Rein Therapeutics Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $11.0M | $14.2M | $4.0M | $18.0M | $17.0M | $11.2M | $17.7M | $18.4M |
| SG&A Expense | $10.9M | $13.9M | $11.4M | $9.7M | $9.6M | $9.3M | $12.3M | $13.5M |
| Operating Income | $-50.6M | $-65.1M | $-16.3M | $-27.6M | $-26.6M | $-20.5M | $-30.0M | $-31.9M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $-712.0K | $-1.5M | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-49.9M | $-62.9M | $-15.7M | $-27.3M | $-26.2M | $-27.3M | $-29.4M | $-31.5M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | $-1.96 | $-3.51 | $-0.86 | $-1.51 | $-1.47 | $-0.15 | $-0.30 | $-0.54 |
| EPS (Diluted) | $-1.96 | $-3.51 | $-0.86 | $-1.51 | $-1.47 | $-0.15 | $-0.30 | $-0.54 |
| Shares Outstanding (Basic) | 25.4M | 17.9M | 18.4M | 18.2M | 17.8M | 175.2M | 111.2M | 59.0M |
| Shares Outstanding (Diluted) | 25.4M | 17.9M | 18.4M | 18.2M | 17.8M | 175.2M | 111.2M | 59.0M |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |